Type Whole antibody Routes of
administration Subcutaneous injection Legal status Investigational | Source Humanized (from mouse) ATC code none | |
Target Proprotein convertase subtilisin/kexin type 9 (PCSK9) | ||
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
Contents
Description
Bococizumab is a monoclonal antibody that inhibits PCSK9, a protein that interferes with the removal of LDL. LDL levels are a major risk factor for cardiovascular disease.
Clinical trials
A phase 2b study of statin patients was presented at the 2014 American College of Cardiology. Monthly or bimonthly injections resulted in significantly reduced LDL-C at week 12.
The Phase 3 SPIRE trials plan to enroll 17,000 patients to measure cardiovascular risk. High risk and statin intolerant subjects will be included.